MetaCap

ImmuCell (ICCC) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImmuCell (ICCC) has outperformed Alpha Teknova (TKNO) over the past year, gaining 133.3% versus a gain of 77.4%. Over five years, ICCC leads with a +18.7% price change compared with -63.6% for TKNO. Alpha Teknova is the larger company by market cap ($480.0 million vs $99.3 million), about 4.8 times the size.

ImmuCell converts more of its revenue into profit, with a net margin of -3.8% versus -42.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ICCC+133.33%TKNO+77.44%
+161%+48%-64%
Nov 21, 20251 yearNov 20, 2026
ICCC+23.53%TKNO-69.50%
+33%-34%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ICCC versus TKNO key metrics
MetricICCCTKNO
Share price$10.92$7.63
Market cap$99.28M$479.95M
1-day change-2.41%-2.30%
YTD return+77.56%+100.79%
1-year return+133.33%+77.44%
5-year return+18.70%-63.63%
P/E ratio (TTM)57.47—
EPS (TTM)$0.19$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.64M$40.52M
Revenue growth (YoY)+4.34%+7.35%
Net income (latest FY)$-1.04M$-17.26M
Gross margin41.40%33.17%
Operating margin5.97%-41.90%
Net margin-3.76%-42.59%
52-week high$12.10$9.48
52-week low$4.67$1.91
Distance from 52-week high-9.75%-19.51%
Analyst consensus—none
Avg. price target upside—+28.83%
Average volume13.44K437.31K
Shares outstanding9.09M62.90M
Employees73158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Alpha Teknova is about 4.8 times larger than ImmuCell by market value ($479.95M vs $99.28M).
  • ICCC has outperformed TKNO by 55.9 percentage points over the past year.
  • ImmuCell is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -42.6 cents for Alpha Teknova.

About ImmuCell

ICCC stock →

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

ICCC vs TKNO FAQ

Which is bigger, ImmuCell or Alpha Teknova?

Alpha Teknova (TKNO) is larger, with a market capitalization of $479.95M compared with $99.28M for ImmuCell (ICCC).

Which stock has performed better over the past year, ICCC or TKNO?

ICCC returned +133.33% over the past 12 months, compared with +77.44% for TKNO (price return, excluding dividends). Past performance does not predict future results.

Are ImmuCell and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons